Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Genor Bio Conducting $370 Million IPO in Hong Kong

publication date: Sep 23, 2020

Genor Biopharma, a Shanghai company, is conducting a Hong Kong IPO that could raise up to $370 million. The company is developing a clinical-stage portfolio of 14 mAbs and recombinant fusion proteins, a combination of novel drugs and biosimilars that target indications in cancer, metabolic and autoimmune diseases. Its PD-1 molecule is currently in four pivotal Phase II trials. In June, Genor completed a $160 million Series B financing led by Beijing's Hillhouse Capital Group. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020